Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy
- 10 June 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (7) , 645-649
Abstract
Introduction: Thyroid-associated ophthalmopathy (TAO) is a disfiguring, potentially blinding, and sub-optimally managed autoimmune condition. Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in 2 clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO. Areas Covered: This article reviews phase II and III placebo controlled, double masked, prospective, multicenter studies assessing the efficacy and safety of teprotumumab for the treatment of active, moderate-to-severe TAO. Expert Opinion: Teprotumumab has demonstrated substantial and rapid improvement in Clinical Activity Score and proptosis reduction in TAO compared to placebo. Subjective diplopia and quality of life were also improved in both clinical trials. Teprotumumab exhibited a favorable safety profile, with transient hyperglycemia, muscle cramps, and auditory side effects being associated with the drug; these were usually transient. The trial findings indicate that teprotumumab is a promising, potential first line therapy for treating active TAO.Keywords
Funding Information
- NIH (EY008976)
- NIH (UM1 Al 110498 05)
- NEI Core (EY007003)
This publication has 36 references indexed in Scilit:
- Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' OrbitopathyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathyBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- The Evaluation and Treatment of Graves OphthalmopathyMedical Clinics of North America, 2012
- Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?Pharmacological Reviews, 2010
- A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid TumorsClinical Cancer Research, 2010
- Increased Generation of Fibrocytes in Thyroid-Associated OphthalmopathyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Orbital irradiation for Graves' ophthalmopathyOphthalmology, 2004
- Orbital Fibroblast Heterogeneity May Determine the Clinical Presentation of Thyroid-Associated OphthalmopathyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture.The Journal of Clinical Endocrinology & Metabolism, 1996
- Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathyThe Lancet, 1993